Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CS Pharma Acquires China Rights to Fibrosis Drug in $336 Million Agreement

publication date: Jan 31, 2023

CS Pharmaceuticals, a London company with offices in Beijing and Shanghai, entered a $336 million agreement for greater China rights to a PRS inhibitor, Bersiporocin, for Idiopathic Pulmonary Fibrosis (IPF) from South Korea’s Daewoong. Daewoong will receive $76 million in upfront and development milestone payments, plus double-digit royalties on sales. CS, a company that brings rare disease and ophthalmology products to China, may extend the indication for Bersiporocin to other respiratory and fibrotic conditions. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital